TenNor Therapeutics (HKG:6872) selected the treatment of prosthetic joint infection via intra-articular injection administration as the core indication of rifaquizinone for prioritized development, a Friday bourse filing showed.
A phase IIb clinical trial, designed to further evaluate the efficacy, safety, and pharmacokinetic profile of rifaquizinone for prosthetic joint infection, has also enrolled the first patient.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments